CNS Pharmaceuticals (CNSP) Prices 3.95M Share Offering at $1.265/sh

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) today announced the pricing of its "reasonable best efforts" public offering with a single healthcare focused institutional investor for the purchase and sale of 3,952,570 shares of common stock of the Company (the "Common Stock) (or common stock equivalents in lieu thereof), at a purchase price of $1.265 per share of Common Stock. The Company further agreed to issue to the investors Series F Common Stock purchase warrants to purchase up to 3,952,570 shares of Common Stock (the "Series F Warrants"). The Series F Warrants will have an exercise price of $1.14 per share, will be exercisable immediately following the date of their issuance and will expire in five years.

The closing of the offering is expected to occur on or about May 14, 2025, subject to the satisfaction of customary closing conditions. The gross proceeds from the offering are expected to be approximately $5 million, before deducting placement agent fees and other estimated offering expenses. The Company intends to use the net proceeds of this offering for working capital and general corporate purposes.

A.G.P./Alliance Global Partners is acting as sole placement agent in connection with the offering.

The securities described above are being offered pursuant to a registration statement on Form S-1, as amended (File No. 333-286529) previously filed with the Securities and Exchange Commission ("SEC") which became effective on May 13, 2025. The offering is being made only by means of a prospectus forming part of the effective registration statement. A preliminary prospectus relating to the offering has been filed with the SEC. An electronic copy of the final prospectus will be filed with the SEC and may be obtained, when available, on the SEC's website located at http://www.sec.gov and may also be obtained from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022, or by telephone at (212) 624-2060, or by e-mail at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

You May Also Be Interested In

• CNS Pharmaceuticals outlines oncology and neurology pipeline strategy
• XTEND deploys XOS-powered AtlasROVER to Asia-Pacific customer
• Polaryx Therapeutics names Will Charlton as chief medical officer